

Supporting Information
for
**Copper-mediated synthesis of *N*-alkenyl- α,β -unsaturated
nitrones and their conversion to tri- and tetrasubstituted
pyridines**

Dimitra Kontokosta, Daniel S. Mueller, Dong-Liang Mo, Wiktorina H. Pace, Rachel A. Simpson and Laura L. Anderson*

Address: Department of Chemistry, University of Illinois at Chicago, 845 W. Taylor St.,
Chicago, IL 60607, U.S.A.

Email: Laura L. Anderson - lauralin@uic.edu

*Corresponding author

Experimental part

Contents:


I.	General experimental information	S2
II.	Synthesis of nitrones 8	S3
III.	Synthesis of pyridines 9	S10
IV.	References	S15
V.	^1H and ^{13}C NMR spectra for nitrones 8	S16
VI.	^1H and ^{13}C NMR spectra for pyridines 9	S38
VII.	^1H and ^{13}C NMR spectra for reaction monitoring	S60

I. General experimental information


^1H NMR and ^{13}C NMR spectra were recorded at ambient temperature using 500 MHz spectrometers. The data are reported as follows: chemical shift in ppm from internal tetramethylsilane on the δ scale, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz), and integration. High-resolution mass spectra were acquired on an LTQ FT spectrometer, and were obtained by peak matching. Analytical thin-layer chromatography was performed on 0.25 mm extra hard silica gel plates with UV_{254} fluorescent indicator. Medium pressure liquid chromatography was performed to force flow the indicated solvent system down columns packed with 60 Å (40–60 μm) mesh silica gel (SiO_2). Unless otherwise noted, all reagents were obtained from commercial sources and, where appropriate, purified prior to use. Anhydrous 1,2-dichloroethane (DCE) was used as received. Anhydrous dimethyl sulfoxide (DMSO) was used as received.

Oximes **6a–e** were reported previously.¹ Alkenylboronic acids **7a–d** were reported previously.² Boronic acid **7e** was obtained from a commercial source.


II. Synthesis of nitrones




General procedure A: A scintillation vial was charged with oxime **6** (1.0 equiv), alkenyl boronic acid **7** (2 equiv), Cu(OAc)₂ (10 mol %), and anhydrous Na₂SO₄ (8–9 equiv). These solids were diluted with DCE to form a 0.1 M solution of oxime. Pyridine (5 equiv) was added to the resulting slurry via syringe, followed by cyclooctadiene (COD) (1.2 equiv). The scintillation vial was then capped with a septum pierced with a ventilation needle and the reaction mixture was stirred at 25 °C for 18 h. DCE and pyridine were removed under reduced pressure and the crude reaction mixture was purified by medium pressure chromatography (2:1; ethyl acetate:hexanes) to give *E*-**8** as a yellow oil or solid. Only the *E*-isomer of the nitronone was observed and isolated.




General procedure B: A scintillation vial was charged with oxime **6** (1.0 equiv), alkenyl boronic acid **7** (2–3 equiv), Cu(OAc)₂ (1–2 equiv), and anhydrous Na₂SO₄ (8–9 equiv). These solids were diluted with DCE to form a 0.1 M solution of oxime. Pyridine (10 equiv) was added to the resulting slurry via syringe. The scintillation vial was then capped with a septum pierced with a ventilation needle and the reaction mixture was stirred at 25 °C for 18 h. DCE and pyridine were removed under reduced pressure and the crude reaction mixture was purified by medium pressure chromatography (2:1; ethyl acetate:hexanes) to give *E*-**8** as a yellow oil or solid. Only the *E*-isomer of the nitronone was observed and isolated.




Nitron 8aa: General procedure **A** was applied using the following reagents: chalcone oxime **6a** (0.030 g, 0.13 mmol), cyclohex-1-enylboronic acid (**7a**, 0.033 g, 0.26 mmol), Cu(OAc)₂ (0.0024 g, 0.013 mmol), pyridine (0.052 mL, 0.65 mmol), COD (0.021 mL, 0.16 mmol), and Na₂SO₄ (0.11 g, 0.77 mmol). This procedure afforded **E-8aa** as a yellow solid (0.028 g, 72%) after purification using medium pressure chromatography (2:1, EtOAc:hexanes). ¹H NMR (500 MHz, CDCl₃): δ 8.00 (d, *J* = 16.4 Hz, 1H), 7.48-7.34 (m, 5H), 7.29-7.19 (m, 5H), 6.54 (d, *J* = 16.4 Hz, 1H), 5.56-5.53 (m, 1H), 2.31-2.23 (m, 2H), 1.82-1.80 (m, 2H), 1.57-1.49 (m, 2H), 1.35-1.32 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 148.5, 144.2, 140.3, 136.3, 133.3, 129.8, 129.1, 129.0, 128.6, 128.3, 127.5, 125.8, 121.6, 26.9, 23.9, 21.9, 21.0; IR (thin film) 3056, 3032, 2932, 2858, 2843, 1665, 1603, 1573, 1500, 1467 cm⁻¹; HRMS (ESI) *m/z* calcd. for C₂₁H₂₂NO (M+H)⁺ 304.1701, found 304.1700.




Nitron 8ba: General procedure **A** was applied using the following reagents: chalcone oxime **6b** (0.030 g, 0.10 mmol), cyclohex-1-enylboronic acid (**7a**, 0.026 g, 0.21 mmol), Cu(OAc)₂ (0.0018 g, 0.010 mmol), pyridine (0.042 mL, 0.51 mmol), COD (0.015 mL, 0.12 mmol), and Na₂SO₄ (0.10 g, 0.70 mmol). This procedure afforded **E-8ba** as a yellow amorphous solid (0.015 g, 41%) after purification using medium pressure chromatography (2:1, EtOAc:hexanes). ¹H NMR (500 MHz, CDCl₃): δ 8.00 (d, *J* = 16.5 Hz, 1H), 7.70 (d, *J* = 8.0 Hz, 2H), 7.52-7.45 (m, 2H), 7.42-7.40 (m, 2H), 7.37-7.27 (m, 3H), 6.50 (d, *J* = 16.5 Hz, 1H), 5.57-5.55 (m, 1H), 2.39-2.26 (m, 2H), 1.96-1.78 (m, 2H), 1.65-1.54 (m, 2H), 1.48-1.31 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 146.8, 144.3, 140.0, 137.2, 136.1, 130.5, 130.3, 129.3 (q, *J*_{C-F} = 225.0 Hz), 128.9, 128.8, 127.5, 126.4, 125.5, 125.4, 27.0, 23.9, 21.9, 21.0; IR (thin film) 3056, 2936, 1617, 1468, 1322, 1269, 1230, 1165, 1123, 1067 cm⁻¹; HRMS (ESI) *m/z* calcd. for C₂₂H₂₁F₃NO (M+H)⁺ 372.1575, found 372.1585.




Nitron 8ca: General procedure **A** was applied using the following reagents: chalcone oxime **6c** (0.040 g, 0.16 mmol), cyclohex-1-enylboronic acid (**7a**, 0.040 g, 0.32 mmol), $\text{Cu}(\text{OAc})_2$ (0.0029 g, 0.016 mmol), pyridine (0.065 mL, 0.80 mmol), COD (0.024 mL, 0.19 mmol), and Na_2SO_4 (0.11 g, 0.77 mmol). This procedure afforded **E-8ca** as a yellow amorphous solid (0.033 g, 63%) after purification using medium pressure chromatography (2:1, EtOAc:hexanes). ^1H NMR (500 MHz, CDCl_3): δ 8.05 (d, $J = 16.4$ Hz, 1H), 7.51 (d, $J = 7.5$ Hz, 2H), 7.37-7.29 (m, 3H), 7.21 (d, $J = 8.3$ Hz, 2H), 6.97 (d, $J = 8.3$ Hz, 2H), 6.61 (d, $J = 16.4$ Hz, 1H), 5.66-5.64 (m, 1H), 2.40-2.20 (m, 2H), 1.95-1.92 (m, 2H), 1.74-1.54 (m, 2H), 1.52-1.38 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 159.9, 148.0, 144.6, 140.1, 136.4, 131.2, 129.0, 128.7, 127.5, 125.6, 125.4, 122.1, 113.8, 55.3, 27.1, 24.0, 22.1, 21.1; IR (thin film) 3039, 2933, 2836, 1606, 1573, 1517, 1447, 1289, 1247, 1223, 1174 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{22}\text{H}_{24}\text{NO}_2$ ($\text{M}+\text{H}$) $^+$ 334.1807, found 334.1800.




Nitron 8da: General procedure **A** was applied using the following reagents: chalcone oxime **6d** (0.022 g, 0.10 mmol), cyclohex-1-enylboronic acid (**7a**, 0.041 g, 0.33 mmol), $\text{Cu}(\text{OAc})_2$ (0.0029 g, 0.016 mmol), pyridine (0.062 mL, 0.80 mmol), and Na_2SO_4 (0.10 g, 0.70 mmol). No COD was added to this reaction mixture. This procedure afforded **E-8da** as a yellow liquid (0.021 g, 70%) after purification using medium pressure chromatography (2:1, EtOAc:hexanes). ^1H NMR (500 MHz, CDCl_3): δ 7.83 (d, $J = 16.3$ Hz, 1H), 7.50-7.34 (m, 4H), 7.34-7.17 (m, 2H), 6.51-6.25 (m, 3H), 5.64-5.48 (m, 1H), 2.31-2.28 (m, 2H), 1.93-1.76 (m, 2H), 1.64-1.50 (m, 2H), 1.44-1.28 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 152.9, 147.7, 144.3, 143.8, 133.4, 129.7, 128.9, 128.4, 126.3, 125.7, 119.9, 112.2, 111.9, 27.0, 23.9, 22.0, 21.0; IR (thin film) 3054, 2932, 2859, 1603, 1501, 1440, 1361, 1264, 1248, 1074 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{20}\text{NO}_2$ ($\text{M}+\text{H}$) $^+$ 294.1485, found 294.1494.




Nitron 8ea: General procedure **A** was applied using the following reagents: dibenzylideneacetone (dba) oxime **6e** (0.025 g, 0.10 mmol), cyclohex-1-enylboronic acid (**7a**, 0.025 g, 0.20 mmol), Cu(OAc)₂ (0.0018 g, 0.010 mmol), pyridine (0.042 mL, 0.50 mmol), COD (0.015 mL, 0.12 mmol), and Na₂SO₄ (0.087 g, 0.61 mmol). This procedure afforded **8ea** as a yellow amorphous solid (0.027 g, 84%) after purification using medium pressure chromatography (2:1, EtOAc:hexanes). ¹H NMR (500 MHz, CDCl₃): δ 7.60-7.55 (m, 2H), 7.50 (d, *J* = 7.9 Hz, 2H), 7.47-7.43 (m, 2H), 7.40-7.36 (m, 4H), 7.35-7.30 (m, 2H), 7.02-6.92 (m, 2H), 6.03-5.95 (m, 1H), 2.56-2.41 (m, 2H), 2.27-2.21 (m, 2H), 1.91-1.77 (m, 2H), 1.78-1.64 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 145.0, 144.3, 139.3, 136.6, 136.3, 134.1, 129.0, 129.0, 128.8, 128.7, 127.4, 126.7, 125.5, 120.3, 119.1, 26.3, 24.2, 22.3, 21.4; IR (thin film) 3024, 2932, 2858, 1493, 1447, 1374, 1304, 1217, 1188, 1074 cm⁻¹; HRMS (ESI) *m/z* calcd for C₂₃H₂₄NO (M+H)⁺ 330.1858, found 330.1851.




Nitron 8ab: General procedure **B** was applied using the following reagents: chalcone oxime **6a** (0.230 g, 1.03 mmol), 2-buten-2-ylboronic acid (**7b**, 0.311 g, 3.12 mmol), Cu(OAc)₂ (0.219 g, 1.20 mmol), pyridine (0.90 mL, 10.0 mmol), Na₂SO₄ (1.35 g, 9.52 mmol). This procedure afforded **E-8ab** as a light yellow amorphous solid (0.042 g, 15%) after medium pressure chromatography (80:20 EtOAc:hexanes). ¹H NMR (500 MHz; CDCl₃) δ 8.03 (d, *J* = 15.0 Hz, 1H), 7.47-7.46 (m, 2H), 7.43-7.40 (m, 3H), 7.32-7.27 (m, 3H), 7.24-7.23 (m, 2H), 6.53 (d, *J* = 15.0 Hz, 1H), 5.44-5.40 (m, 1H), 1.91 (s, 3H), 1.41 (d, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz) δ 148.2, 142.0, 140.3, 136.3, 133.4, 129.8, 129.1, 129.0, 128.7, 128.5, 127.5, 123.7, 121.8, 15.2, 12.4; IR (thin film) 3055, 2925, 2854, 1663, 1604, 1449, 1335, 1214, 1015, 747 cm⁻¹; HRMS (ESI) *m/z* calcd. for C₁₉H₂₀NO (M+H)⁺ 278.1545, found 278.1542.




Nitron 8bb: General procedure **B** was applied using the following reagents: dba oxime **6b** (0.260 g, 1.04 mmol), 2-buten-2-ylboronic acid (**7b**, 0.346 g, 3.46 mmol), Cu(OAc)₂ (0.212 g, 1.17 mmol), pyridine (0.80 mL, 10.0 mmol), Na₂SO₄ (1.24 g, 8.74 mmol). This procedure afforded **8bb** as an amorphous yellow solid (0.22 g, 68%) after medium pressure chromatography (60:40 EtOAc:hexanes). ¹H NMR (500 MHz; CDCl₃) δ 7.59-7.57 (m, 2H), 7.53-7.50 (m, 2H), 7.45-7.44 (m, 2H), 7.37 (q, *J* = 7.3 Hz, 4H), 7.33-7.31 (m, 2H), 6.95 (s, 2H), 5.72-5.68 (m, 1H), 2.12 (s, 3H), 1.79 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (125 MHz) δ 144.6, 141.9, 139.2, 136.7, 136.4, 134.0, 129.0, 128.9, 128.8, 128.7, 127.4, 126.8, 123.2, 120.4, 119.1, 14.6, 12.8; IR (thin film) 3055, 3025, 2925, 1694, 1597, 1447, 1216, 1191, 963, 753 cm⁻¹; HRMS (ESI) *m/z* calcd. for C₂₁H₂₂NO (M+H)⁺ 304.1701, found 304.1702.




Nitron 8ac: General procedure **B** was applied using the following reagents: chalcone oxime **6a** (0.066 g, 0.30 mmol), 1-phenylbut-1-enylboronic acid (**7c**, 0.16 g, 0.90 mmol), Cu(OAc)₂ (0.11 g, 0.59 mmol), pyridine (0.24 mL, 3.0 mmol), and Na₂SO₄ (0.30 g, 2.11 mmol). This procedure afforded **E-8ac** as a yellow liquid (0.061 g, 57%) after purification using medium pressure chromatography (2:1, EtOAc:hexanes). ¹H NMR (500 MHz; CDCl₃): δ 8.10 (d, *J* = 16.5 Hz, 1H), 7.46 (d, *J* = 6.5 Hz, 2H), 7.35-7.22 (m, 9H), 7.13-7.12 (m, 2H), 7.03 (d, *J* = 8.0 Hz, 2H), 6.53 (d, *J* = 16.5 Hz, 1H), 5.97 (t, *J* = 7.5 Hz, 1H), 2.06-2.01 (m, 2H), 0.87 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 149.2, 145.3, 140.1, 136.3, 133.7, 132.8, 130.5, 129.2, 129.1, 128.8, 128.7, 128.3, 128.2, 128.1, 128.0, 127.6, 121.9, 21.2, 13.4; IR (thin film) 3025, 2965, 1681, 1598, 1575, 1493, 1447, 1274, 1213, 1175, 1071 cm⁻¹; HRMS (ESI) *m/z* calcd. for C₂₅H₂₄NO (M+H)⁺ 354.1858, found 354.1852.



Nitronium 8ad: General procedure **B** was applied using the following reagents: chalcone oxime **6a** (0.066 g, 0.30 mmol), hex-1-enylboronic acid (**7d**, 0.10 g, 0.78 mmol), Cu(OAc)₂ (0.11 g, 0.59 mmol), pyridine (0.24 mL, 3.0 mmol), and Na₂SO₄ (0.36 g, 2.53 mmol). This procedure afforded **E-8ad** as a yellow liquid (0.068 g, 75%) after purification using medium pressure chromatography (2:1, EtOAc:hexanes). ¹H NMR (500 MHz; CDCl₃): δ 8.19 (d, *J* = 16.5 Hz, 1H), 7.52-7.40 (m, 5H), 7.30-7.26 (m, 5H), 6.89-6.83 (m, 1H), 6.61 (d, *J* = 13.0 Hz, 1H), 6.50 (d, *J* = 16.5 Hz, 1H), 2.06-2.01 (m, 2H), 1.36-1.33 (m, 2H), 1.29-1.25 (m, 2H), 0.85 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 147.9, 140.9, 136.4, 132.0, 130.9, 130.3, 129.7, 129.3, 129.0, 128.8, 128.7, 127.6, 122.5, 30.8, 29.0, 22.1, 13.7; IR (thin film) 3052, 2929, 1712, 1604, 1575, 1448, 1364, 1335, 1264, 1216 cm⁻¹; HRMS (ESI) *m/z* calcd. for C₂₁H₂₄NO (M+H)⁺ 306.1858, found 306.1860.




Nitronium 8ae: General procedure **B** was applied using the following reagents: chalcone oxime **6a** (0.066 g, 0.30 mmol), (*p*-fluorostyryl)boronic acid (**7e**, 0.15 g, 0.90 mmol), Cu(OAc)₂ (0.11 g, 0.59 mmol), pyridine (0.24 mL, 3.0 mmol), and Na₂SO₄ (0.36 g, 2.53 mmol). This procedure afforded **E-8ae** as a yellow solid (0.085 g, 83%) after purification using medium pressure chromatography (2:1, EtOAc:hexanes). ¹H NMR (500 MHz; CDCl₃): δ 8.27 (d, *J* = 16.5 Hz, 1H), 7.72 (d, *J* = 13.0 Hz, 1H), 7.57-7.55 (m, 3H), 7.51-7.49 (m, 2H), 7.40-7.38 (m, 2H), 7.32-7.31 (m, 3H), 7.26-7.21 (m, 3H), 6.97-6.94 (m, 2H), 6.58 (d, *J* = 16.5 Hz, 1H); ¹³C NMR (125 MHz, CDCl₃): δ 164.1 (d, *J*_{C-F} = 248.0 Hz), 149.5, 141.6, 136.4, 131.9, 130.8, 130.5, 130.1, 129.5, 129.3, 129.1, 128.8, 128.6, 127.8, 126.9, 122.5, 116.0; IR (thin film) 3111, 3056, 1965, 1887, 1741, 1631, 1599, 1569, 1507, 1446 cm⁻¹; HRMS (ESI) *m/z* calcd. for C₂₃H₁₉FNO (M+H)⁺ 344.1451, found 344.1449.




Nitrone 8fa/8fa': General procedure **A** was applied using the following reagents: oxime **6f** (0.119 g, 0.427 mmol), cyclohexenylboronic acid (**7a**, 0.181 g, 1.43 mmol), Cu(OAc)₂ (0.0080 g, 0.044 mmol), pyridine (0.17 mL, 2.1 mmol), cyclooctadiene (64 μ L, 0.47 mmol), and Na₂SO₄ (0.589 g, 4.15 mmol). This procedure afforded **8fa:8fa'** as a yellow oil (0.12 g, 76%) and as a 1:1 mixture of nitrone isomers after medium pressure chromatography (60:40 EtOAc:hexanes). ¹H NMR (500 MHz; CDCl₃) *E*- and *Z*-isomers were coincidental δ 7.57 (d, *J* = 10 Hz, 1H), 7.52 (d, *J* = 10 Hz, 1H), 7.49-7.43 (m, 3H), 7.40-7.35 (m, 4H), 7.33-7.31 (m, 1H), 6.95 (m, 1H), 6.92-6.85 (m, 3H), 5.91-5.89 (m, 1H), 3.83 (s, 3H), 2.49-2.47 (m, 2H), 2.24-2.21 (m, 2H), 1.85-1.81 (m, 2H), 1.71-1.68 (m, 2H); ¹³C NMR (125 MHz; CDCl₃) *E*- and *Z*-isomers were distinguishable δ 160.5, 145.3, 139.3, 136.7, 134.1, 129.4, 129.0, 128.9, 128.8, 128.2, 127.4, 125.4, 120.4, 119.3, 114.5, 55.4, 26.3, 24.2, 22.3, 21.5; ¹³C NMR of other isomer (125 MHz; CDCl₃) δ 160.3, 144.3, 139.1, 136.4, 133.9, 129.1, 129.0, 128.8, 128.2, 127.4, 126.8, 125.3, 118.2, 116.9, 114.3, 55.3, 26.2, 24.2, 22.3, 21.5; IR (thin film) 3022, 2938, 2860, 1701, 1601, 1510, 1249, 1172, 1104, 1030 cm⁻¹; HRMS (ESI) *m/z* calcd. for C₂₄H₂₆NO₂ (M+H)⁺ 360.1964, found 360.1964.


III. Synthesis of pyridines



General procedure C: A Teflon-sealed reaction flask was charged with nitron **8**, 4 Å molecular sieves (3 beads) and DMSO (0.1 M) and solution was heated at 140 °C for 6–8 h. The solution was then diluted with EtOAc (10 mL) and extracted with water. The aqueous layer was extracted twice with EtOAc (2 × 10 mL), and the combined organic extracts were washed with brine (1 × 10 mL). The organic layer was dried with MgSO₄ and concentrated under vacuum. The crude product mixture was purified by medium pressure chromatography (15:85, EtOAc:hexanes) to give **9** as a light yellow oil.




Pyridine 9aa:³ General procedure C was applied using nitron **8aa** (0.031 g, 0.10 mmol). This procedure afforded **9aa** as a yellow oil (0.020 g, 71%) after purification using medium pressure chromatography (15:85, EtOAc:hexanes). ¹H NMR (500 MHz, CDCl₃): δ 7.99-7.96 (m, 2H), 7.49-7.42 (m, 5H), 7.39-7.35 (m, 2H), 7.37-7.33 (m, 2H), 3.10 (t, *J* = 6.5 Hz, 2H), 2.66 (t, *J* = 6.3 Hz, 2H), 2.02-1.90 (m, 2H), 1.84-1.68 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 157.6, 154.3, 150.3, 139.7, 128.9, 128.6, 128.5, 128.4, 128.3, 128.0, 127.7, 126.9, 119.1, 33.3, 27.3, 23.1, 23.0; IR (thin film) 3057, 2932, 2859, 1587, 1542, 1495, 1439, 1419, 1381, 1264, 1073 cm⁻¹; HRMS (ESI) *m/z* calcd for C₂₁H₂₀N (M+H)⁺ 286.1596, found 286.1599.




Pyridine 9ba: General procedure C was applied using nitron **8ba** (0.027 g, 0.074 mmol). This procedure afforded **9ba** as a yellow amorphous solid (0.018 g, 68%) after purification using medium pressure chromatography (15:85, EtOAc:hexanes). ¹H NMR (500 MHz, CDCl₃): δ 8.11 (d, *J* = 8.1 Hz, 2H), 7.69 (d, *J* = 8.1 Hz, 2H), 7.49-7.41 (m,


4H), 7.36-7.33 (m, 2H), 3.11 (t, $J = 6.6$ Hz, 2H), 2.68 (t, $J = 6.3$ Hz, 2H), 2.06-1.88 (m, 2H), 1.84-1.71 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 158.1, 152.5, 139.3, 130.9, 129.6, 129.0, 128.8, 128.7, 128.5, 128.4, 127.9, 127.1, 125.6 (q, $J_{\text{C-F}} = 204.0$ Hz), 119.4, 33.2, 27.3, 23.0, 22.9; IR (thin film) 2937, 1714, 1587, 1541, 1496, 1449, 1322, 1264, 1164, 1108, 1067 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{22}\text{H}_{19}\text{F}_3\text{N}$ ($\text{M}+\text{H}$) $^+$ 354.1470, found 354.1463.




Pyridine 9ca:^{3a} General procedure C was applied using nitrone **8ca** (0.015 g, 0.047 mmol). This procedure afforded **9ca** as a yellow oil (0.010 g, 64%) after purification using medium pressure chromatography (15:85, EtOAc:hexanes). ^1H NMR (500 MHz, CDCl_3): δ 7.93 (d, $J = 8.7$ Hz, 2H), 7.48-7.43 (m, 2H), 7.43-7.39 (m, 1H), 7.36-7.32 (m, 3H), 6.97 (d, $J = 8.7$ Hz, 2H), 3.85 (s, 3H), 3.08 (t, $J = 6.6$ Hz, 2H), 2.64 (t, $J = 6.3$ Hz, 2H), 2.01-1.86 (m, 2H), 1.82-1.68 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 160.1, 157.3, 141.1, 140.1, 139.8, 128.5, 128.3, 128.1, 127.7, 127.5, 127.2, 118.5, 114.0, 55.3, 33.29, 29.72, 27.25, 23.12; IR (thin film) 2931, 2856, 1606, 1587, 1513, 1494, 1449, 1414, 1379, 1249, 1171 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{22}\text{H}_{22}\text{NO}$ ($\text{M}+\text{H}$) $^+$ 316.1701, found 316.1702.




Pyridine 9da:⁴ General procedure C was applied using nitrone **8da** (0.016 g, 0.046 mmol). This procedure afforded **9da** as a yellow oil (0.012 g, 76%) after purification using medium pressure chromatography (15:85, EtOAc:hexanes). ^1H NMR (500 MHz, CDCl_3): δ 8.04-7.99 (m, 2H), 7.90 (s, 1H), 7.60-7.58 (m, 1H), 7.48-7.44 (m, 2H), 7.41-7.38 (m, 1H), 6.78 (d, $J = 3.4$ Hz, 1H), 6.57 (dd, $J = 3.4, 1.8$ Hz, 1H), 3.19-3.06 (m, 2H), 2.94 (t, $J = 6.2$ Hz, 2H), 2.05-1.81 (m, 4H); ^{13}C NMR (125 MHz, CDCl_3) δ 162.8, 161.9, 158.0, 143.0, 128.6, 128.4, 128.1, 126.9, 126.8, 126.5, 115.4, 112.1, 111.8, 27.9, 27.7, 23.1, 22.7; IR (thin film) 2930, 1712, 1594, 1565, 1546, 1491, 1445, 1368, 1264, 1026 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{19}\text{H}_{18}\text{NO}$ ($\text{M}+\text{H}$) $^+$ 276.1388, found 276.1389.



Pyridine 9ea: General procedure C was applied using nitrone **8ea** (0.050 g, 0.15 mmol). This procedure afforded **9ea** as a yellow oil (0.020 g, 43%) after purification using medium pressure chromatography (15:85, EtOAc:hexanes). ^1H NMR (500 MHz, CDCl_3): δ 7.59-7.54 (m, 2H), 7.51 (d, $J = 16.2$ Hz, 1H), 7.48-7.43 (m, 2H), 7.43-7.40 (m, 1H), 7.38-7.31 (m, 4H), 7.30-7.27 (m, 1H), 7.22-7.18 (m, 2H), 3.05 (t, $J = 6.6$ Hz, 2H), 2.63 (t, $J = 6.4$ Hz, 2H), 2.01-1.87 (m, 2H), 1.83-1.68 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.4, 152.5, 139.5, 136.9, 131.8, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.7, 126.9, 119.8, 33.2, 27.4, 23.0, 23.0; IR (thin film) 3026, 2933, 2859, 1712, 1581, 1537, 1495, 1449, 1386, 1264, 1073 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{23}\text{H}_{22}\text{N}$ ($\text{M}+\text{H}$) $^+$ 312.1752, found 312.1750.




Pyridine 9ab:⁵ General procedure C was applied using nitrone **8ab** (0.0421 g, 0.152 mmol). This procedure afforded **9ab** as a yellow oil (0.0198 g, 50%) after purification using medium pressure chromatography (5:95, EtOAc:hexanes). ^1H NMR (500 MHz, CDCl_3): δ 7.58-7.55 (m, 3H), 7.48-7.45 (m, 1H), 7.43-7.41 (m, 1H), 7.37-7.32 (m, 3H), 7.28-7.26 (m, 1H), 7.20-7.17 (m, 2H), 2.63 (s, 3H), 2.20 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.7, 151.9, 149.9, 140.1, 137.0, 131.5, 128.7, 128.6, 128.3, 128.0, 127.7, 126.9, 120.4, 23.6, 16.2; IR (thin film) 3055, 3022, 2922, 1580, 1545, 1495, 1448, 1388, 966, 779 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{19}\text{H}_{18}\text{N}$ ($\text{M}+\text{H}$) $^+$ 260.1439, found 260.1437.




Pyridine 9eb: General procedure C was applied using nitrone **8eb** (0.0642 g, 0.212 mmol). This procedure afforded **9eb** as a yellow oil (0.0217 g, 36%) after purification using medium pressure chromatography (5:95, EtOAc:hexanes). ^1H NMR (500 MHz, CDCl_3): δ 7.58-7.55 (m, 3H), 7.48-7.45 (m, 2H), 7.43-7.32 (m, 5H), 7.29-7.27 (m, 1H), 7.20-7.17 (m, 2H), 2.63 (s, 3H), 2.20 (s, 3H); ^{13}C NMR (125 MHz, CDCl_3) δ 157.7, 152.0, 150.0, 140.1, 137.0, 131.6, 128.8, 128.7, 128.4, 128.3, 128.0, 127.7, 127.6, 127.0,


120.5, 23.7, 16.2; IR (thin film) 3058, 2967, 1721, 1575, 1495, 1416, 1257, 1087, 964, 761 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{20}\text{N}$ ($\text{M}+\text{H}$)⁺ 286.1596, found 286.1592.



Pyridine 9ac:⁶ General procedure C was applied using nitrone **8ac** (0.090 g, 0.25 mmol). This procedure afforded **9ac** as a yellow oil (0.073 g, 87%) after purification using medium pressure chromatography (15:85, EtOAc:hexanes). ¹H NMR (500 MHz, CDCl_3): δ 8.08 (d, $J = 7.5$ Hz, 2H), 7.63 (d, $J = 7.5$ Hz, 2H), 7.58 (s, 1H), 7.51-7.44 (m, 10H), 7.39 (t, $J = 7.0$ Hz, 1H), 2.74 (q, $J = 7.5$ Hz, 2H), 0.81 (t, $J = 7.5$ Hz, 3H); ¹³C NMR (125 MHz, CDCl_3): δ 159.6, 153.7, 151.4, 141.7, 140.4, 139.2, 133.5, 129.1, 128.8, 128.7, 128.6, 128.5, 128.4, 128.2, 127.7, 127.0, 120.7, 22.2, 14.9; IR (thin film) 3057, 2970, 1714, 1584, 1575, 1491, 1443, 1415, 1374, 1264, 1087 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{25}\text{H}_{22}\text{N}$ ($\text{M}+\text{H}$)⁺ 336.1752, found 336.1759.




Pyridine 9ad:⁷ General procedure C was applied using nitrone **8ad** (0.059 g, 0.20 mmol). This procedure afforded **9ad** as a yellow oil (0.038 g, 71%) after purification using medium pressure chromatography (15:85, EtOAc:hexanes). ¹H NMR (500 MHz, CDCl_3): δ 8.59 (s, 1H), 8.01 (d, $J = 8.0$ Hz, 2H), 7.57 (s, 1H), 7.47-7.39 (m, 6H), 7.36-7.35 (m, 2H), 2.61 (t, $J = 7.5$ Hz, 2H), 1.48-1.45 (m, 2H), 1.27-1.24 (m, 2H), 0.82 (t, $J = 7.5$ Hz, 3H); ¹³C NMR (125 MHz, CDCl_3): δ 154.8, 150.7, 150.0, 139.5, 139.2, 134.1, 129.0, 128.7, 128.5, 128.4, 127.9, 126.7, 121.3, 33.2, 29.7, 22.3, 13.7; IR (thin film) 3057, 2958, 2860, 2361, 1592, 1576, 1474, 1446, 1375, 1265, 1216 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{21}\text{H}_{22}\text{N}$ ($\text{M}+\text{H}$)⁺ 288.1752, found 288.1750.



Pyridine 9ae: General procedure C was applied using nitrone **8ae** (0.047 g, 0.14 mmol). This procedure afforded **9ae** as a yellow oil (0.029 g, 65%) after purification using


medium pressure chromatography (15:85, EtOAc:hexanes). ^1H NMR (500 MHz, CDCl_3): δ 8.70 (s, 1H), 8.10-8.06 (m, 2H), 7.77 (s, 1H), 7.53-7.48 (m, 2H), 7.47-7.44 (m, 1H), 7.32-7.29 (m, 3H), 7.23-7.19 (m, 2H), 7.17-7.12 (m, 2H), 7.00-6.96 (m, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.2 (d, $J_{\text{C-F}} = 246.2$ Hz), 156.4, 150.4, 138.7, 133.4, 131.4, 131.3, 129.2, 129.1, 128.8, 128.6, 128.4, 128.1, 126.9, 121.7, 115.4, 115.3; IR (thin film) 3057, 1711, 1586, 1537, 1510, 1494, 1471, 1443, 1367, 1264, 1222, 1158 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{23}\text{H}_{17}\text{FN}$ ($\text{M}+\text{H}$) $^+$ 326.1345, found 326.1340.




Pyridine 9fa: General procedure C was applied using nitrone **8fa:8fa'** (0.0895 g, 0.249 mmol). This procedure afforded **9fa:9fa'** as a yellow oil (0.0272 g, 32%) after purification using medium pressure chromatography (40:60, EtOAc:hexanes). ^1H NMR of **9fa:9fa'** (500 MHz, CDCl_3): δ 7.56 (d, $J = 5$ Hz, 1H), 7.52-7.39 (m, 3H), 7.38-7.32 (m, 2H), 7.28-7.27 (m, 1H), 7.21-7.15 (m, 2H), 7.09-7.05 (m, 1H), 6.98 (d, $J = 5$ Hz, 1H), 6.89 (d, $J = 5$ Hz, 1H), 3.87 (s, 3H), 3.05-3.02 (m, 2H), 2.67-2.61 (m, 2H), 1.94-1.91 (m, 2H), a second OMe resonance indicated the presence of the other isomer δ 3.82 (s, 3H); ^{13}C NMR of pyridine **9fa** (125 MHz, CDCl_3) δ 159.6, 157.5, 150.0, 139.7, 131.6, 129.8, 128.7, 128.5, 128.3, 128.2, 128.0, 127.0, 126.5, 120.0, 114.1, 55.4, 33.3, 27.6, 27.4, 23.1; ^{13}C NMR of pyridine **9fa'** (125 MHz, CDCl_3) δ 159.3, 157.4, 149.7, 137.0, 131.3, 129.8, 128.7, 128.5, 128.3, 128.2, 127.7, 127.0, 126.5, 119.5, 113.8, 55.4, 33.3, 27.4, 23.0; IR (thin film) 3061, 2930, 2857, 1607, 1510, 1450, 1246, 1174, 1033, 830 cm^{-1} ; HRMS (ESI) m/z calcd. for $\text{C}_{24}\text{H}_{24}\text{NO}$ ($\text{M}+\text{H}$) $^+$ 342.1858, found 342.1863.


IV. References:

1. a) Mo, D.-L.; Anderson, L. L. *Angew. Chem. Int. Ed.* **2013**, *52*, 6722-6725; b) Mo, D.-L.; Pecak, W. H.; Zhao, M.; Wink, D. J.; Anderson, L. L. *Org. Lett.* **2014**, *16*, 3696-3699.
2. a) Patil, A. S.; Mo, D.-L.; Wang, H.-Y.; Mueller, D. S.; Anderson, L. L. *Angew. Chem. Int. Ed.* **2012**, *51*, 7799-7803; b) Kontokosta, D.; Mueller, D. S.; Wang, H.-Y.; Anderson, L. L. *Org. Lett.* **2013**, *15*, 4830-4833.
3. a) Gezegen, H.; Dingil, A.; Ceylan, M. *J. Heterocycl. Chem.* **2010**, *47*, 1017-1024; b) Katritzky, A. R.; Awartani, R. *Tetrahedron* **1982**, *38*, 2505-2512.
4. Banerjee, C. K.; Umarye, J. D.; Kanjilal, P. R. *Synth. Commun.* **2013**, *43*, 2208-2216.
5. Yamamoto, S.-I.; Okamoto, K.; Murakoso, M.; Kuninobu, Y.; Takai, K. *Org. Lett.* **2012**, *14*, 3182-3185.
6. Fischer, G. W. *J. Prakt. Chem.* **1985**, *327*, 983-997.
7. Liu, S.; Liebeskind, L. S. *J. Am. Chem. Soc.* **2008**, *130*, 6918-6919.



8aa








8aa

27.02
26.26
24.16
23.92
22.32
22.01
21.51
21.05

148.28
144.37
140.14
136.38
134.26
133.39
129.98
129.84
129.08
129.02
128.87
128.70
128.38
127.52
127.26
126.77
125.81
124.76
122.04
121.72









8ba

27.06
23.93
21.96
21.00


146.81
144.32
140.03
137.27
136.10
130.58
130.36
129.36
128.95
128.80
127.56
126.46
125.45
125.41
121.34






8ca

- 8.07
- 8.03
- 7.52
- 7.50
- 7.35
- 7.34
- 7.32
- 7.31
- 7.21
- 7.20
- 6.97
- 6.96
- 6.92
- 6.59
- 5.65
- 3.89
- 2.29
- 2.31
- 1.94
- 1.94
- 1.93
- 1.60
- 1.59
- 1.45
- 1.43
- 1.42





8ca

21.16
22.13
24.02
27.08

55.37

113.83

122.08

125.47

125.62

127.57

128.74

129.05

131.29

136.48


140.06

144.60

148.04

159.96

f1 (ppm)




8da


1.36
1.36
1.37
1.37
1.38
1.54
1.55
1.55
1.56
1.57
1.84
1.85
1.85
2.28
2.28
2.29
2.29
2.30
2.30
2.30
2.31

5.55
5.56
5.56
5.57

6.39
6.40
6.40
6.41
6.42
7.23
7.24
7.39
7.40
7.40
7.41
7.43
7.43

7.81
7.84






8da

- 152.98
- 147.77
- 144.38
- 143.84
- 133.40
- 129.78
- 128.96
- 128.40
- 126.38
- 125.79
- 119.97
- 112.21
- 111.99


- 27.03
- 23.94
- 22.03
- 21.07




1.69
1.70
1.70
1.71
1.72
1.83
1.84
1.84
1.85
1.86
2.23
2.23
2.24
2.25
2.48
2.48
2.48
2.49
2.49
2.50


5.91
5.91
5.92
5.92
5.93

6.93
6.97
6.98
7.02
7.31
7.32
7.32
7.33
7.33
7.34
7.36
7.37
7.39
7.40
7.44
7.45
7.45
7.50
7.51
7.57
7.59
7.59



8ea







8ea

S25

26.32
24.21
22.33
21.48


145.00
144.31
139.32
136.62
136.37
134.12
129.00
128.78
126.78
120.32
119.11






8ab


8.04
8.01
7.48
7.47
7.46
7.43
7.42
7.41
7.41
7.40
7.32
7.31
7.30
7.29
7.27
7.26
7.24
7.24
7.23
7.23
6.55
6.52
5.42
5.41
1.91
1.42
1.41







8ba


148.17
142.02
140.28
136.34
133.43
129.79
129.11
128.97
128.72
128.48
127.54
123.69
121.78
15.19
12.42






8eb






8eb

S29






8ac

8.10
8.07
7.45
7.30
7.29
7.28
7.27
7.26
7.23
7.02
6.53
6.50
5.96
5.94
5.93
2.08
2.06
2.05
2.03
2.02
0.87
0.86
0.84

1.00
3.34
12.10
2.52
2.24
1.02
0.98
2.18
3.10

11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5


f1 (ppm)




8ac

149.15
145.29
144.87
140.09
136.34
134.77
133.78
132.87
132.80
131.59
130.53
129.93
129.20
129.14
128.98
128.85
128.72
128.64
128.53
128.45
128.33
128.24
128.11
128.04
127.82
127.59
126.81
126.69
122.14
121.91


21.66
21.20
14.01
13.44






8ad

8.20
8.17
7.52
7.51
7.45
7.29
6.87
6.62
6.59
6.50
6.46
2.05
1.35
1.28
0.84





8ad


147.65
140.64
136.49
132.13
130.81
129.70
129.22
128.95
128.75
127.61
122.51


77.10

30.87
29.05

22.12

13.76







8ae

S34


- 8.282
- 8.249
- 7.733
- 7.706
- 7.572
- 7.569
- 7.560
- 7.559
- 7.509
- 7.495
- 7.393
- 7.390
- 7.382
- 7.376
- 7.339
- 7.326
- 7.311
- 7.302
- 7.289
- 7.241
- 7.238
- 7.226
- 7.219
- 7.215
- 7.209
- 6.976
- 6.958
- 6.941
- 6.589
- 6.557






8ae


S35




1.68
1.68
1.69
1.70
1.70
1.71
1.71
1.81
1.82
1.83
1.84
1.85
2.21
2.21
2.22
2.23
2.23
2.24
2.24
2.47
2.48
2.49
3.83
5.89
5.91
5.91
6.85
6.88
6.89
6.91
6.92
6.95
6.95
6.95
7.31
7.32
7.33
7.35
7.35
7.35
7.36
7.37
7.38
7.39
7.40
7.43
7.44
7.46
7.48
7.49
7.51
7.53
7.56
7.58




8fa






8fa


S37





9aa

follows: $O_2(g) + H_2(g) \rightleftharpoons CO(g) + H_2O(g)$
 with $K_p = 1.56$
 at a partial pressure of 0.250 atm,
 (1) P_{CO}
 equilibrium
 of gas
 four gases.




7.99
7.99
7.97
7.47
7.47
7.46
7.46
7.46
7.45
7.45
7.44
7.43
7.42
7.42
7.41
7.39
7.39
7.38
7.36
7.36
7.34

3.12
3.10
3.09
2.68
2.66
2.65
1.96
1.95
1.95
1.94
1.94
1.78
1.77
1.77
1.76
1.75

2.00
4.69
2.37
1.95

2.05
1.94
2.20
2.47




9aa



33.36
27.32
23.13
23.07



128.66
128.57
128.48
128.35
127.76
126.90
119.16



139.73


157.64
154.31
150.31











9ca

33.29
29.72
27.25
23.12
23.08


55.36

114.04

118.51

127.73
128.14
128.33
128.55

f1 (ppm)




9da

S44

1.88
1.89
1.89
1.90
1.91
1.94
1.94
1.95
1.95
1.96
1.97
2.93
2.94
2.95
3.10
3.11
3.12

6.56
6.57
6.57
6.58
6.77
6.77
6.78
7.45
7.47
7.47
7.48
7.59
7.59
7.90
8.01
8.01
8.02
8.03




27.96
23.06
22.71

128.65
128.43
128.09
126.97
126.88
126.50
115.45
112.16
111.84


143.03


162.82
161.97
158.01



9da

S45






9ea


3.06
3.05
3.04
2.65
2.63
2.62
1.94
1.93
1.92
1.76
1.75
1.74
1.74
1.73
1.73


7.58
7.57
7.56
7.52
7.49
7.47
7.46
7.45
7.44
7.44
7.42
7.42
7.40
7.37
7.37
7.36
7.36
7.34
7.34
7.34
7.33
7.33
7.32
7.32
7.32
7.29
7.27
7.23
7.20
7.19




2.12
2.15
2.25
2.36


2.00
1.03
2.07
0.96
4.18
0.88
2.07







9ab





9ab







9eb


7.58
7.57
7.55
7.48
7.47
7.46
7.45
7.43
7.42
7.41
7.38
7.36
7.35
7.34
7.34
7.32
7.29
7.28
7.26
7.20
7.18
7.17


2.63
2.20





9eb







9ac

0.79
0.78
0.76

2.73
2.71
2.70
2.68

7.26
7.37
7.38
7.38
7.39
7.39
7.41
7.41
7.42
7.43
7.43
7.44
7.44
7.45
7.45
7.47
7.47
7.48
7.49
7.49
7.50
7.50
7.50
7.57
7.60
7.61
7.62
7.62
8.05
8.05
8.06
8.07
8.07







9ac

- 159.63
- 153.72
- 151.32
- 141.76
- 140.41
- 139.28
- 129.06
- 128.59
- 128.57
- 128.36
- 126.95
- 120.66

- 22.22
- 14.90





9ad

0.79
0.81
0.82
1.23
1.24
1.26
1.27
1.44
1.45
1.47
1.48
1.50
2.64
2.65
2.67

7.26
7.35
7.37
7.39
7.41
7.42
7.44
7.46
7.47
7.49
7.57
8.00
8.01
8.59

3.26
2.62
2.24

2.11


1.12
2.33
6.39
1.07

2.08

1.00

11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5

f1 (ppm)



9ad


— 13.72
— 22.36
— 29.71
— 33.18

121.28
126.74
127.86
128.42
128.56
128.66
128.70
128.92
134.10
139.38
139.88
150.07
150.79
154.95

230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10

f1 (ppm)


8.71
8.09
8.08
8.07
8.07
8.07
7.78
7.53
7.52
7.51
7.51
7.50
7.49
7.47
7.46
7.45
7.33
7.32
7.32
7.31
7.22
7.21
7.21
7.20
7.20
7.17
7.16
7.16
7.15
7.14
7.14
7.00
7.00
6.99
6.98
6.97





9ae

S56

1.84
1.93
1.83
2.56
1.09
1.92
1.02
2.02







9fa

9fa'

3.05
3.03
3.02
2.67
2.65
2.64
2.63
2.62
2.61
1.94
1.93
1.91
1.76
1.75
1.74
1.74
1.73
1.73

3.87
3.82

7.57
7.56
7.52
7.51
7.49
7.49
7.47
7.46
7.45
7.44
7.43
7.41
7.39
7.38
7.37
7.36
7.34
7.33
7.32
7.28
7.26
7.21
7.18
7.17
7.15
7.09
7.05
6.99
6.98
6.90
6.89


1.95
6.04
4.12
3.19
3.55
1.65
2.27
2.02

3.26
3.01

4.29
4.17

4.00
4.04






9fa

9fa'

159.64
 159.27
 157.47
 157.37
 152.91
 152.53
 149.99
 149.69
 139.68
 136.99
 131.63
 131.33
 129.80
 128.66
 128.53
 128.31
 128.26
 127.98
 127.71
 126.97
 126.46
 120.03
 119.52
 114.14
 113.76
 55.35
 55.32
 33.28
 27.56
 27.40
 23.12
 23.06



8.65
8.35
8.26
8.19
8.17
8.14
8.13
8.07
8.01
7.97
7.95
7.92
7.90
7.88
7.86
7.76
7.66
7.64
7.56
7.53
7.51
7.49
7.47
7.45
7.44
7.32
7.28
7.27
7.24
7.22
7.21
7.13
7.12
7.10
7.06
7.04
7.02
7.00
6.99
6.96
6.95
6.93
6.90
6.88
6.85
6.57
6.44
6.41
6.10
6.06
5.81
5.63
5.37
2.48




CH₂Br₂ (internal standard)

enaminoketone

isoxazoline

pyridine



11.5 10.5 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 -1.5

f1 (ppm)

